Chugai licenses diabetes project CSG452 to Kowa, Sanofi
Executive Summary
Roche unit Chugai Pharmaceutical Co. Ltd. has granted Sanofi KK and Kowa Co. Ltd. rights to develop and co-market the Type II diabetes compound CSG452 in Japan.
Deal Industry
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Co-Marketing
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice